Publications

Bhinder B, Friedl V, Sethuraman S, Risso D, Chiotti KE, R Mashl J, Ellrott KP, Lee JA, Wong CK, Gyan K et al..  2025.  Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles.. Sci Rep. 15(1):23921.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM et al..  2013.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.. Blood. 122(18):3165-8.

Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al..  2016.  Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, Johnson KEnnu, Hanna S, Askan G, Burman J et al..  2024.  Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer.. Nat Med. 30(8):2170-2180.

Bose A, Liu W, Yoo P, Sami A, Boniecki MT, Deshpande M, Osman M, Nguyen D, Castillo UD, Giannakakou P et al..  2025.  APOBEC3A-Induced DNA Damage Drives Polymerase θ Dependency and Synthetic Lethality in Cancer.. bioRxiv.

Bovonratwet P, Kulm S, Kolin DA, Song J, Morse KW, Cunningham ME, Albert TJ, Sandhu HS, Kim HJo, Iyer S et al..  2023.  Identification of Novel Genetic Markers for the Risk of Spinal Pathologies: A Genome-Wide Association Study of 2 Biobanks.. J Bone Joint Surg Am. 105(11):830-838.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.

Brendel M, Getseva V, Assaad MAl, Sigouros M, Sigaras A, Kane T, Khosravi P, Mosquera JMiguel, Elemento O, Hajirasouliha I.  2022.  Weakly-supervised tumor purity prediction from frozen H&E stained slides.. EBioMedicine. 80:104067.

Brendel M, Su C, Bai Z, Zhang H, Elemento O, Wang F.  2022.  Application of Deep Learning on Single-cell RNA Sequencing Data Analysis: A Review.. Genomics Proteomics Bioinformatics. 20(5):814-835.

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, Chan WKeung, Prouty A, Chung J-H, Zhang Y et al..  2023.  PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.. Blood Adv. 7(20):6211-6224.

Bruno NE, Nwachukwu JC, Srinivasan S, Nettles CC, Izard T, Jin Z, Nowak J, Cameron MD, Boregowda SV, Phinney DG et al..  2021.  Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.. Nat Chem Biol. 17(3):307-316.

Bunting KL, T Soong D, Singh R, Jiang Y, Béguelin W, Poloway DW, Swed BL, Hatzi K, Reisacher W, Teater M et al..  2016.  Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region.. Immunity. 45(3):497-512.

Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.

Buqué A, Bloy N, Petroni G, Jiménez-Cortegana C, Sato A, Iribarren C, Yamazaki T, Galassi C, Hensler M, Bhinder B et al..  2025.  Impact of radiation therapy dose, fractionation, and immunotherapeutic partner in a mouse model of hormone receptor-positive mammary carcinogenesis.. J Natl Cancer Inst. 117(5):934-947.

Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):4787.

Campbell TL, De Silva EK, Olszewski KL, Elemento O, Llinás M.  2010.  Identification and genome-wide prediction of DNA binding specificities for the ApiAP2 family of regulators from the malaria parasite.. PLoS Pathog. 6(10):e1001165.

Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.

Cárdenas MG, Yu W, Béguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest. 126(9):3351-62.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.. Cell Rep. 34(8):108784.

Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TChedraoui, Wong CK, Choi HYoung, Felau I, A Robertson G et al..  2021.  Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.. Cell Rep. 34(5):108707.

Carty M, Zamparo L, Sahin M, González A, Pelossof R, Elemento O, Leslie CS.  2017.  An integrated model for detecting significant chromatin interactions from high-resolution Hi-C data.. Nat Commun. 8:15454.

Carty MA, Elemento O.  2016.  Practical Analysis of Genome Contact Interaction Experiments.. Methods Mol Biol. 1418:177-89.

Casiraghi N, Orlando F, Ciani Y, Xiang J, Sboner A, Elemento O, Attard G, Beltran H, Demichelis F, Romanel A.  2020.  ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA.. Bioinformatics. 36(9):2665-2674.

Ceballos-Chávez M, Subtil-Rodríguez A, Giannopoulou EG, Soronellas D, Vázquez-Chávez E, Vicent GP, Elemento O, Beato M, Reyes JC.  2015.  The chromatin Remodeler CHD8 is required for activation of progesterone receptor-dependent enhancers.. PLoS Genet. 11(4):e1005174.